Search PubMed⌕ Search

Biomedical subjects

M Lucsko

Publications and source records attributed to M Lucsko.

At least 55 records · Page 3Linked to original sources
PubMed1975

[Acebutolol in the treatment of arterial hypertension. Clinical study].

Fifty hypertensive patients were given a beta-blocker, acebutolol, alone or in association with other hypotensive drugs, in an open therapeutic trial lasting for a year. The results of treatment were considered to be good or moderate in 74 p.cent of the patients. Treatment failures were recorded in 26 p.cent. The mean dosage of acebutolol was 10 mg/kg (maximum 22 mg/kg) and the drug was very well tolerated. Hypertension with an increased cardiac index and reno-vascular hypertension with increased plasma renin activity are good indications for acebutolol.

Acebutolol↗
PubMed1975

[Test with trinitrine. Clinical evaluation of the beta anti-adrenergic effect of acebutolol in arterial hypertension].

The beta-adrenergic stimulation test with nitroglycerin, described by Fitzgerald, was used to monitor antihypertensive treatment with the beta-blocker acebutolol in 30 hypertensive patients. The nitroglycerin-induced tachycardia was reduced by acebutolol and this allowed the degree of beta-blockage to be estimated. It would also be possible, by tests performed before treatment, to select hypotensive patients who could be highly responsive to beta-adrenergic blockers, for whom there are the best prospects of success.

Acebutolol↗
PubMed1975

Late streptokinase therapy in thrombotic microangiopathy: a case study.

A 42 year woman presented with malignant hypertension, anuria and hemolytic anemia with schistocytosis. The diagnosis of thrombotic microangiopathy was confirmed by early renal biopsy. Purely symptomatic treatment (peritoneal dialysis and hypotensive drugs) was supplemented by administration of heparin and Dipyridamole. Gastro-intestinal bleeding prevented early thrombolytic therapy. Microangiopathic anemia rapidly disappeared but anuria persisted. Three months later a second renal biopsy showed persistence of active lesions and absence of irreversible parenchymal damage. Streptokinase treatment was then instituted and followed by a rapid return of urinary output. Hemodialysis was stopped and renal function continued to improve over the following months. Two years later the patient remains well despite persistence of hypertension difficult to control. Creatinine clearance is stable at 20 ml/min. This observation suggests that late thrombolytic therapy may be effective in patients with thrombotic microangiopathy when histological findings do not indicate extensive irreversible lesions.

Adult↗
PubMed1974

[Hemodynamic and hormonologic basis of the treatment of arterial hypertension].

The efficiency and the variety of drugs used in the treatment of arterial hypertension demand that the various disorders responsible for the blood pressure increase be well individualized. The study of the haemodynamic and hormonal factors and of their interelations in the patients provides interesting informations which make it possible to classify the hypertensive subjects according to physiopathological criteria. Starting from these data, it is possible to consider a rational treatment by selecting the drugs acting specifically on the anomalies to be corrected.

Adrenergic beta-Antagonists↗
PubMedDate not supplied

Clinical pharmacology of prazosin in hypertensive patients with chronic renal failure.

The clinical pharmacology of prazosin was studied in 10 hypertensive patients with chronic renal failure (group I) and in 9 hypertensive patients with normal renal function (group II). Prazosin, 2 mg, was given orally and blood samples were drawn at intervals for spectrofluorimetric assay. Blood pressure and heart rate were obtained at the same time. In the renal failure group, prazosin induced a significant decrease in systolic and diastolic blood pressures (-19 and -23%, respectively) at 90 min after intake, and these alterations were more rapid and marked than in the normal renal function group. Peak plasma concentration (Cmax) was higher (33.5 +/- 3.7 vs. 20.04 +/- 1.7 micrograms/liter, p < 0.01) and occurred earlier (1.3 +/- 0.2 vs. 2.7 +/- 0.3 hr, p < 0.005) in group I than in group II. The area under the plasma concentration-time curve (AUC0 infinity) was increased in the renal failure group (206.1 +/- 31.1 vs. 112.4 +/- 9.4 micrograms/hr/liter, p < 0.01). Apparent plasma elimination half-life (t 1/2) was not significantly different in the two groups (3.6 +/- 0.4 vs. 2.9 +/- 0.3 hr. ns). The mean blood pressure change (delta MBP%) was significantly correlated with the plasma level of prazosin in the renal failure group (n = 97, r = 0.489, p < 0.001) but not in patients with normal renal function (n = 74, r = 0.297, ns). The hypotensive action of prazosin is greater in patients with chronic renal failure, and the bioavailability or distribution of the drug is altered. Therefore, prazosin dosages should be modified in patients with impaired renal function.

Adult↗
PubMedDate not supplied

Acute and chronic effects of a new calcium inhibitor, nicardipine, on renal hemodynamics in hypertension.

Renal hemodynamics and natriuresis were studied in 10 hypertensive patients without renal failure, 2 and 4 h after oral intake of 30 mg nicardipine; then, nicardipine was given at a dose of 30 mg three times a day and the hemodynamic study was repeated on the 6th day (2 h after the morning dose). The first dose of nicardipine produced an increase in renal blood flow (from 888 +/- 45 to 999 +/- 59 ml/min 1.73 m2, p less than 0.01) and a decrease in renal vascular resistances (from 0.16 +/- 0.01 to 0.12 +/- 0.01 arbitrary unit, p less than 0.05). Glomerular filtration rate did not change and the decrease in filtration fraction was not significant. Sodium excretion increased markedly during the first 2 h (from 0.17 +/- 0.04 to 0.29 +/- 0.06 mmol/min, p less than 0.05). On the 6th day renal vascular resistances and filtration fraction remained lowered whereas glomerular filtration rate was unchanged. Nicardipine did not produce any significant alteration in plasma renin activity and plasma aldosterone after acute or chronic administration. These results confirm the potent renal vasodilatory effect of nicardipine; glomerular filtration rate was not significantly altered whereas renal blood flow and filtration fraction returned to normal levels. An early and transient natriuretic effect was observed after the first dose of nicardipine, and body weight showed a significant decrease during the study indicating that no sodium retention was induced by nicardipine.

Adult↗